Clinical research observations with use of exubera in patients with type 1 and 2 diabetes.
Cefalu
William T
WT
Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana 70808, USA. cefaluwt@pbrc.edu
Wang
Zhong Q
ZQ
D000280:Administration, Inhalation; D000284:Administration, Oral; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004867:Equipment Design; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000097:blood; D009330:Nebulizers and Vaporizers; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D007330:Insulin Antibodies; D000077154:Rosiglitazone; D045162:Thiazolidinediones; C473734:Exubera